Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2013

View Archived Issues

Researchers publish report on chemically attenuated low-dose parasite-containing antimalaria vaccine

New renin inhibitors for the treatment of hypertension revealed by Daiichi Sankyo

Researchers in Poland present new caspase-3 and -7 activators

Plasma markers correlate with obstructive sleep apnea syndrome severity

Champions Oncology and Teva sign drug development agreement

Tetraphase describes novel tetracycline antibacterials

Evotec AG and Harvard Stem Cell Institute form CureMN collaboration

Mount Sinai grants Plexcera license to develop rhAC-based treatments

Circassia reports phase II findings for house dust mite allergy treatment

GlaxoSmithKline receives FDA priority review for dabrafenib/trametinib sNDAs

FDA grants breakthrough therapy designation to ofatumumab for previously untreated CLL

EMA grants orphan drug status to GMI-1070 in sickle cell disease

Data from phase II study of brincidofovir for preventing adenovirus disease presented

Cubist Pharmaceuticals completes acquisition of Trius Therapeutics

Ganymed obtains CE Mark for Claudetect 18.2 test

Bullet Biotechnology updates on financing and product development

Taiho Pharmaceutical divulges new Aurora kinase A inhibitors

Regeneron describes human monoclonal IgG4 antibodies targeting big ET-1

FDA lifts clinical hold on Pluristem's study of PLX-PAD for intermittent claudication

Adaptive Biotechnologies receives SBIR grant

Arbor Pharmaceuticals to market and sell Edarbi and Edarbyclor in U.S.

Swissmedic accepts for review ceftobiprole MAA for pneumonia

Astellas Pharma reports discovery of dual 5-HT2B/5-HT7 receptor antagonists for IBS

Alemtuzumab approved for multiple sclerosis in the E.U.

Tolvaptan approved in Japan to treat fluid retention in patients with hepatic cirrhosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...